Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.
Jiangsu Hengrui Pharmaceuticals has announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its self-developed Class 1 innovative drug, Fosrolapitant and Palonosetron Hydrochloride for Injection. This drug, designed to prevent acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy in adults, marks China’s first ultra-long-acting original compound antiemetic injection. This approval is a significant milestone for the company, potentially enhancing its market position in the oncology sector and providing a new treatment option for patients undergoing chemotherapy.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, specializing in the development and production of innovative drugs. The company focuses on creating treatments for various medical conditions, with a significant emphasis on oncology and chemotherapy-related products.
Average Trading Volume: 27,396,529
Current Market Cap: HK$369.6B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.